drugset
drugset / Trial / NCT02936492

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

NCT02936492 ↗

Phase 1 Terminated 32 enrolled Bayer
RandomizedParallel-groupDouble-blindOther

Summary

Systemic safety following single and multiple dermal administration of BAY1003803

Timeline

Start
2016-10-24
Primary completion
2017-04-18
Completion
2017-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BAY1003803 Unknown 0.01 % Topical
Subject BAY1003803 Unknown 0.1 % Topical
Subject BAY1003803 Unknown 0.13 mg Topical
Subject BAY1003803 Unknown 61.7 mg Topical
Comparator clobetasol propionate Small molecule 16.5 mg Topical

Indications

psoriasis